230 related articles for article (PubMed ID: 21677472)
1. Kidney cancer pathology in the new context of targeted therapy.
Allory Y; Culine S; de la Taille A
Pathobiology; 2011; 78(2):90-8. PubMed ID: 21677472
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
3. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling in renal cell carcinoma.
Dizman N; Philip EJ; Pal SK
Nat Rev Nephrol; 2020 Aug; 16(8):435-451. PubMed ID: 32561872
[TBL] [Abstract][Full Text] [Related]
5. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
6. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
[TBL] [Abstract][Full Text] [Related]
7. [Molecular tumor board-renal cell carcinoma].
Grünwald V; Doehn C; Goebell PJ
Urologe A; 2019 Jul; 58(7):768-773. PubMed ID: 31175376
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
9. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark PE
Kidney Int; 2009 Nov; 76(9):939-45. PubMed ID: 19657325
[TBL] [Abstract][Full Text] [Related]
10. Renal-cell carcinoma--molecular pathways and therapies.
Brugarolas J
N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
[No Abstract] [Full Text] [Related]
11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
13. Oncotargets in different renal cancer subtypes.
Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
[TBL] [Abstract][Full Text] [Related]
14. [Current strategies in the treatment of renal-cell cancer: targeted therapies].
Trigo JM; Bellmunt J
Med Clin (Barc); 2008 Mar; 130(10):380-92. PubMed ID: 18381031
[TBL] [Abstract][Full Text] [Related]
15. Papillary renal cell carcinoma: current progress and future directions.
Twardowski PW; Mack PC; Lara PN
Clin Genitourin Cancer; 2014 Apr; 12(2):74-9. PubMed ID: 24629521
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy in renal cell carcinoma.
Rathmell WK; Wright TM; Rini BI
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1031-40. PubMed ID: 16336094
[TBL] [Abstract][Full Text] [Related]
17. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
18. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
19. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
20. [New drugs for metastatic kidney cancer].
Doehn C
Aktuelle Urol; 2008 Jan; 39(1):41-52. PubMed ID: 18228187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
